ICU Medical, Inc. (ICUI)

Over the past six months, ICU Medical's stock price has declined by 4.45%. Key events impacting the stock include the Q3 2025 earnings announcement where the company beat EPS and revenue estimates, insider stock sales in November 2025, analyst ratings with an average recommendation of "Moderate Buy" and varying price targets, and presentations at healthcare conferences.

Specific details regarding the demand seasonality for ICU Medical's products and services are not explicitly outlined in the provided information. The medical device industry may experience relatively stable demand, though factors like budget cycles of healthcare institutions or widespread health events could introduce some fluctuations. The company's business model emphasizes an installed base plus consumable attachment and software integration to secure recurring revenue, with disposables driving a significant portion of recurring revenue, which could mitigate strong seasonality effects.

ICU Medical, Inc. is a medical technology company focused on developing, manufacturing, and selling medical products for infusion therapy, vascular access, and vital care applications. The company's product portfolio includes infusion therapy products, oncology products, vascular access products, and vital care products.

ICU Medical, Inc. has a global presence with operations in the Americas, Europe, Asia Pacific, Africa, and the Middle East. Its manufacturing footprint covers North America, Mexico, Europe, and Asia. The company's headquarters are located in San Clemente, California, USA.

ICU Medical was recognized as one of the "100 Most Trustworthy Companies in America" by Forbes Magazine in 2014. The company's continued development and FDA clearances of new infusion devices, designed to improve medication delivery accuracy and simplify user experience, likely contribute positively to its reputation for innovation and patient safety.

ICU Medical, Inc. is primarily controlled by institutional investors, holding approximately 89.59% to 96.10% of the shares. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Individual and insider ownership are relatively low, with CEO Vivek Jain making significant purchases.